Abstract
Background Real-time reverse transcription polymerase chain reaction (RT-qPCR) is the current recommended laboratory method to diagnose SARS-CoV-2 acute infection, several factors such as requirement of special equipment, time consuming, high cost and skilled staff limit the use of these molecular techniques. A more rapid and high-throughput method is in growing demand.
Methods Evaluate the performances of the Panbio™ COVID-19 AG Rapid Test Device (Nasopharyngeal), a rapid immunochromatographic test for the detection of SARS-CoV-2 antigen, in comparison to RT-qPCR.
Results The RDT evaluated in this study showed a high sensitivity and specificity in samples mainly obtained during the first week of symptoms and with high viral loads.
Conclusions This assay seems to be an effective strategy for controlling the COVID-19 pandemic for the rapid identification and isolation of SARS-CoV-2 infected patients.
Introduction
Ensuring accurate diagnosis is essential to limit the spread of SARS-CoV-2 and for the clinical management of COVID-19. Although real-time reverse transcription polymerase chain reaction (RT-qPCR) is the current recommended laboratory method to diagnose SARS-CoV-2 acute infection, several factors such as requirement of special equipment, time consuming, high cost and skilled staff limit the use of these molecular techniques. A more rapid and high-throughput method is in growing demand. (1,2)
Until now, the use of antigen detection tests alone had been ruled out and not recommended due to their low sensitivity (3-5). Previously in the first wave, several easy to perform rapid antigen detection tests were developed as the first line of diagnostic. However, the results obtained were not good enough. (6-9)
Material and methods
Population and study period
Study was conducted between September 10, 2020 and September 15, 2020. We included patients that were attended at our emergency department and in two of our primary healthcare centers:
Emergency department
(ED) patients: we included 135 symptomatic patients that were admitted in our ED with clinical suspicion or COVID-19 and 17 asymptomatic patients with history of contact with another COVID-19 patient.
Primary healthcare
(PH) patients: 50 symptomatic patients and 55 asymptomatic patients attendend in two of our primary healthcare centres.
A total of two consecutive nasopharyngeal swabs were obtained from each patient. One of them was employed to perform the antigenic rapid test and the other sample was employed to carry out the RT-PCR.
Diagnostic procedures
RT-PCR
one automatic extractor was employed to obtain viral RNA from clinical samples: Hamilton Microlab Starlet (Hamilton Company, Bonaduz, Switzerland). RNA amplification was made using Allplex SARS-CoV-2 assay (Seegene, Seoul, South Korea).
Antigenic rapid test
we applied the Panbio COVID-19 Ag Rapid Test Device (Abbott Rapid Diagnostic Jena GmbH, Jena, Germany). This test is a qualitative membrane-based immunoassay (immunochromatography) for the detection of Nucleocapsid protein of SARS-CoV-2 in nasopharyngeal samples.
Clinical data
Demographic (age and sex) and clinical variables of the study population were obtained from the medical records. We also recorded the time from the onset of symptoms and the story of prior contact with COVID-19 patients.
Statistical analysis
Specificity and sensitivity with 95% confidence intervals (95%CI) were calculated using the RT-PCR results as gold standard. Sensitivity was evaluated globally and also according to the time from the onset of symptoms (< 7 days and > 7 days). Additionally, we also calculated the negative predictive value (NPV) and positive predictive value (PPV) for estimated prevalence of infection of 1%, 2.5%, 5% and 10%. Agreement between techniques was evaluated using Cohen’s kappa score. (10)
Continuous variables were presented as median and interquartile range (IQR) and categorical variables as proportions. We used the Mann-Whitney U-test, χ2 test, or Fisher’s exact test to compare differences between survivors and non-survivors where appropriate. For these comparisons, a p value of 0.05 or below was considered significant. Statistical analysis was performed with SPSS v20.0 (IBM Corp., Armonk, NY, USA).
Results
255 nasopharyngeal swabs collected from symptomatic and asymptomatic patients were tested. 60 (23,5%) positive RT-qPCR samples, 44 (17,2%) were detected by the rapid antigen test. Overall, amongst the 60 positive samples, the Ct value was detected for gene N in 53 samples. The COVID-19 Ag detected 43 samples (81.1%) (Table 3). The range of cycle threshold (Ct) values was 10.84-37.65 (median 22.32 IQR 18.31-29.02). For samples with Ct < 25 (n = 33), <30 (n = 7), <35 (n = 2) and <40 (n=1), COVID-19 Ag has a sensitivity of 100%, 87.5%, 25% and 25% respectively. However, in our study population, the overall sensitivity is 73.3% (95% IC: 62.2–83.8). Considering only symptomatic patients with less of seven days since onset, the sensitivity is 86.5% (95% IC: 75.0-97.0). Specificity is always 100%.
Patients.
Agreement between antigenic test and PCR.
Color scale stepped from white to gray of median of Cycle threshold (Ct), number of positive results for antigen test and PCR test and sensitivity of antigen test considering days since onset of a) symptoms or contact and b) only symptoms. *Number of positive results
The RDT evaluated in this study showed a high sensitivity and specificity in samples mainly obtained during the first week of symptoms and with high viral loads (table 2)
COVID-19 antigen results according to viral load.
Discussion
As of September 18, 2020, the Food and Drug Administration (FDA) has approved more tan 150 SARS-CoV-2 RNA detection kits. (11,12) The lateral flow assay (LFA) is user-friendly, cheap, and easily mass-produced. In addition, it may be the optimal method for in-field detection of SARS-CoV-2 antigens if accurate, easy-to-use, rapid, and cost-effective. (13)
Our results suggest that Panbio ™ COVID-19 AG Rapid Test Device can rapidly identify SARS-CoV-2-infected individuals with moderate to high viral loads. Antigenic tests have shown 100% specificity in all types of patients and can be a powerful tool of high positive predictive value to control the COVID pandemia. It could be used as a substitute technique for PCR in this type of patients to shortcut delays and intensive labour costs generated by the massive use of PCRs.
In the group of symptomatic patients with less than 7 days of evolution, the test reaches a sensitivity of 86,5%, low to that described in the technical data sheet of the test. It is necessary to carry out studies with more patients to assess the usefulness that this technique could have in evaluating the infective potential of close contacts with PCR positive patients (14,15). When testing with antigen tests, it must be considered that the infection prevalence and the clinical context of the recipient of the test affects at the pretest probability of the result being correct. Also, rapid antigen tests could be used for screening in high-risk clusters settings to identify quickly persons with a SARS-CoV-2 infection and prevent the transmission by repeat testing.
Data Availability
The data that support the findings of this study are available from the corresponding author, M.Linares, upon reasonable request.
Abbreviations
- COVID-19
- Coronavirus disease 2019
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2
- NP
- Nucleocapsid protein
- LFA
- Lateral flow assay
- FDA
- Food and Drug Administration
- RT-qPCR
- Real-time reverse transcription polymerase chain reaction
- RDT
- Rapid diagnostic test.
